Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Asthma Healthy Volunteers Be a man or woman between 18 to 60 years of age, inclusive, at the time of signing the informed consent Cohorts 1, 2 & 3 women of childbearing potential must have a documented menstrual period prior to the first dose and be willing to use 2 forms of appropriate methods of contraception from screening until 4 months after the final dose of RV1729, OR Women of non-childbearing potential must be spontaneously amenorrhoeic for at least 1 year or have been permanently sterilised, OR If a man, must be willing and able to use one of the contraception methods listed in the protocol and agree not to donate sperm from screening until 4 months after the final dose of RV1729 Women must agree not to donate eggs (ova, oocytes) from screening until at least 6 months after the final dose of RV1729 Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study Body mass index between 19 and 30 kg/m2 and body weight not less than 50 kg Vital sign assessments within normal ranges Have a 12-lead ECG recording consistent with normal cardiac function Capable of complying with all study restrictions and procedures including ability to use the study inhaler correctly Cohorts 1, 2 & 4 (healthy volunteers only)  Upper or lower respiratory tract infection within 4 weeks before screening Clinically significant abnormal values for haematology, clinical chemistry or urinalysis at screening or Day -1 Has a history of or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease History of, or a reason to believe a subject has a history of drug or alcohol abuse within the past 5 years Positive test for alcohol or drugs of abuse, including cannabinoids, alcohol, opiates, cocaine, amphetamines, benzodiazepines or barbiturates at screening or on Day -1 History of clinically significant allergies that, in the opinion of the Investigator or Medical Monitor, would contraindicate their participation Subjects known to suffer from hayfever, or other allergy, that may require antihistamine therapy during the course of the study Known allergy to the study drug or any of the excipients of the formulation or has previously been exposed to RV1729 Donated blood or blood products or had substantial loss of blood (more than 500 mL) within 3 months or intention to donate blood or blood products during the study Received an experimental drug or used an experimental medical device within 3 months or within a period less than 10 times the drug's half-life, whichever is longer, before the first dose of the study drug is scheduled